个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
扈金萍,女,研究员,硕士生导师。
河北医科大学药学学士,首都医科大学药理学硕士,北京协和医学院药理学博士。现于中国医学科学院药物研究所工作,先后任助理研究员、副研究员、研究员。2009年-2010年作为访问学者于美国纽约州卫生署研修。
目前主要从事新药药代动力学、药物代谢酶及转运蛋白的研究,包括活性先导物药代特性的早期评价,药物代谢酶/转运蛋白调控的分子机制及生物学效应,新药PK/PD研究等。参与完成多个新药(布格呋喃、IMMH001、IMMH002、MTC-220等)临床前药代动力学研究及临床报批工作。近年来作为课题负责人先后主持国家自然科学基金1项,中央级公益科研院所基本科研业务费3项。同时,作为主要完成人先后参与国家自然科学基金、北京市科委重点基金,全球结核药物研发联盟,政府间国际科技创新合作重点专项、国家“十一五”“十二五”“十三五”新药重大专项,国家科技部“863项目”、“药代技术平台” 建设等国家级课题14项。到目前为止,发表相关论文60余篇,其中SCI收录的有50余篇,参与申请的专利有10项,参与编书2项。
上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpeg上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpeg上传附件
支持扩展名:.rar .zip .doc .docx .pdf .jpg .png .jpeg“国家重点研发计划—政府间国际科技创新合作重点专项”
—PGM3 抑制剂作为胰腺导管腺癌创新疗法的临床前评估(药代负责人)
代表性论文(第一作者/通讯作者)
1. Manman Zhao, Jiaqi Mi, Baolian Wang, Qiong Xiao, Yulin Tian, JinpingHu*, Yan Li*. Insights into the metabolic characteristics ofaminopropanediol analogues of SYLs as S1P1 modulators: from structure tometabolism. European Journal of Pharmaceutical Sciences 158 (2021) 105608
2. Jinping Hu ,Jie Zhou, Yanhong Sun, HuixinTan, Fenghe Wang, Shuainan Liu, Bailing Xu, YanLi,Zhufang Shen*.Quantitative determination of Cpd118, A novelFBPase inhibitor, in dog plasma by HPLC–MS/MS. Bioanalysis(2021) 13(11),865–873.
3. Minwan Hu1, Yang Li1, Feng You, Jie Bai, XiaoqingFan, Shengyu Zhao, Yanhong Sun, Baolian Wang*, Jinping Hu*, Yan Li. Comparisonand identification of metabolic profiling of bicyclol in rats, dogs and humansin vitro and in vivo. European Journal of Pharmaceutical Sciences154 (2020):105518
4. Qiong Xiao1, Minwan Hu1, Si Chen, Zeyu Shi, JinpingHu*, Ping Xie*, Dali Yin*.Design and synthesis of analogues of thesphingosine-1-phosphate receptor 1 agonist IMMH001 with improvedphosphorylation rate in human blood. Bioorganic & Medicinal Chemistry 28(2020) 115722
5. Xiaoqing Fan, Jie Bai, Minwan Hu, Yanxia Xu , Shengyu Zhao, Yanhong Sun,Baolian Wang, Jinping Hu*, Yan Li. Drug interaction study of flavonoidstoward OATP1B1 and their 3D structure activity relationship analysis forpredicting hepatoprotective effects. Toxicology, 2020, 437:152445
6. Jie Bai, Li Li, Shengyu Zhao, Xiaoqing Fan, Jie Zhang, Minwan Hu, YonghuiChen, Yanhong Sun, Baolian Wang, Jing Jin, Xiaojian Wang, Dan Zhang, JinpingHu*, Yan Li. Heterotropic activation of flavonoids on cytochrome P4503A4: A case example of alleviating dronedarone-induced cytotoxicity. Toxicology Letters, 2020, 319: 187-196.
7. Xiao Q, Hu M, Chen S, Tang Y, Shi Z, Jin J, Hu J*, Xie P*,Yin D*. Design and synthesis ofselective sphingosine-1-phosphate receptor 1 agonists with increasedphosphorylation rates. Acta Pharmaceutica Sinica B, 2020, 10: 1134-1142.
8. Shengyu Zhao, Rubing Wang, Jie Bai., Xiaoqing Fan, Minwan Hu, BaolianWang, Jinping Hu*, Yan Li. Simultaneous determination of a promisinganti-brain tumor agent CAT3 and its two major metabolites in mouse plasma andbrain by a LC-MS/MS method. J Pharm Biomed Anal, 2020, 181: 113106.
9. Xiao Q, Hu M, Chen S, Jin J, Li L, Hu J*, Xie P*,Yin D*.S1P1-selective agonist prodrug IMMH002 is phosphorylated in rats to form anS-configured enantiomer: Synthesis, verification, and biological activity ofthe in vivo active metabolite. Bioorganic & Medicinal Chemistry Letters,2020, 30: 127141.
10. Jie Bai, Shengyu Zhao, Xiaoqing Fan, Yonghui Chen, Xiaowen Zou, MinwanHu, Baolian Wang, Jing Jin, Xiaojian Wang, Jinping Hu*, Dan Zhang*, YanLi. Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo:Food/herb-drug interactions and structure-activity relationships. Toxicologyand Applied Pharmacology, 2019, 369: 49-59
11. Xiaoqing Fan, Jie Bai, Shengyu Zhao, Minwan Hu,Yanhong Sun, BaolianWang,Ming Ji, Jing Jin, Xiaojian Wang, Jinping Hu*,Yan Li. Evaluation ofinhibitory effects of flavonoids on breast cancer resistance protein (BCRP):From library screening to biological evaluation to structure-activityrelationship[J]. Toxicology in Vitro, 2019, 61: 104642.
12. Jiaqi Mi, Manman Zhao, Shu Yang, Yufei Jia, Yan Wang, Baolian Wang, JingJin, Xiaojian Wang, Qiong Xiao, Jinping Hu*, Yan Li*. Identification ofcytochrome P450 isoforms involved in the metabolism of Syl930, a selectiveS1PR1 agonist acting as a potential therapeutic agent for autoimmuneencephalitis. Drug Metabolism and Pharmacokinetics. 2017; 32(1):53-60
13. Jiaqi Mi, Manman Zhao, Shu Yang, Shuang Yang, Jing Jin, Xiaojian Wang,Qiong Xiao, Jinping Hu*, Yan Li* Pharmacokinetics of H002, a novelS1PR1 modulator, and its metabolites in rat blood using liquidchromatography–tandem mass spectrometry. Acta Pharmaceutica Sinica B. 2016;6(6):576–583
14. Manman Zhao, Jiaqi Mi, Dan Li, Xin Liu, Shuang Yang, Baolian Wang, LiSheng, Xiaojian Wang, Jing Jin, Jinping Hu*, Yan Li* Quantitativedetermination of2-amino-2-(2-(4′-(2-propyloxazol-4-yl)-[1,1-biphenyl]-4-yl)ethyl)propane-1,3-dioland its active phosphorylated metabolite in ratblood by LC–MS/MS andapplication to PK/PD analysis. Anal Bioanal Chem (2015)407:7511–7516
15. Hu J, Sheng L, Li L, Zhou X, XieF, D'Agostino J, Li Y, Ding X. Essential Role of the Cytochrome P450 EnzymeCYP2A5 in Olfactory Mucosal Toxicity of Naphthalene. DrugMetab Dispos. 2014 Jan; 42(1):23-7.
16. Hu J, You F, Yang S, Li Y.Quantitative determination of Lx2-32 C, a novel taxane derivative, in ratplasma by liquid chromatography–tandem mass spectrometry. Journal ofPharmaceutical and Biomedical Analysis. 88:483-488,2014
17. Jin J1, Hu J1, Zhou W, Wang X, Xiao Q, XueN, Yin D*, Chen X*. Development of a selective S1P1 receptor agonist, Syl930,as a potential therapeutic agent for autoimmune encephalitis. BiochemPharmacol. 2014Jul 1; 90(1):50-61.
文件上传中...